CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Lisocabtagene maraleucel 治疗一例青少年复发/难治性原发纵隔大 B 细胞淋巴瘤
英文原题：Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient.
查看英文原题
Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法在复发/难治性原发纵隔大B细胞淋巴瘤（R/R PMBCL）儿童和青少年患者中的安全性和有效性尚不明确，该病预后极差。在此，我们报告一例16岁R/R PMBCL患者接受lisocabtagene maraleucel治疗的病例报告，包括相关性研究。患者在第6个月达到完全缓解，未发生细胞因子释放综合征和免疫效应细胞相关神经毒性综合征。她仅出现轻度血细胞减少，需要一次非格司亭。本报告强调了lisocabtagene maraleucel在该人群中的安全性和有效性，值得开展前瞻性研究以改善临床结局。
展开英文摘要原文
The safety and efficacy of CAR T-cell therapy are unknown in pediatric and adolescent patients with relapsed or refractory primary mediastinal large B-cell lymphoma (R/R PMBCL) which is associated with dismal prognosis.
Here, we present a case report of a 16-year-old patient with R/R PMBCL treated with lisocabtagene maraleucel including correlative studies. Patient achieved complete response at 6 months without cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. She only experienced mild cytopenias, requiring filgrastim once. This report highlights the safety and efficacy of lisocabtagene maraleucel in this population, warranting prospective studies to improve clinical outcomes.
论文信息
- 作者
- Lee D、Goyal A、Wang WL、Ananth S、Lau E、Binkley MS、Bharadwaj S、Dahiya S
- 第一作者单位
- Division of Hematology Stanford University School of Medicine Stanford California USA.United States
- 通讯作者单位
- Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USA.United States
- 期刊
- EJHaem2024 Feb
- 原文标识
- PubMed 38406546 · DOI 10.1002/jha2.859
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →